Volume 40, Issue 1, July 2023, Pages 279–290
Imane Radouane1, S. Ouahid2, Hasna Igorman3, Rachid Laroussi4, Abdelfettah Touibi5, Sanaa Berrag6, Tarik Adioui7, and Mouna Tamzaourte8
1 Department of Gastroenterology I, Military Hospital, Mohamed V University of Rabat, Morocco
2 Service de Gastroentérologie clinique, Hôpital Militaire d’Instructions Mohammed V, Rabat, Morocco
3 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
4 Department of Gastroenterology I, Military Hospital, Mohamed V University of Rabat, Morocco
5 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
6 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
7 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
8 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
Original language: English
Copyright © 2023 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction: The advent of biotherapies has radically changed the management of IBD. However, the use of these drugs may in some cases result in to primary non-response or a loss of secondary response. Therapeutic Drug Monitoring (TDM) is a tool that was developed to manage biotherapy as accurately as possible in these situations. Material and methods: This is a retrospective descriptive study spread over 8 years of 53 patients followed for IBD put on anti-TNF(, in whom assays of residual levels of anti-TNF and anti-drug antibodies were carried out. Results: 48 suffer from Crohn’s disease and 5 from ulcerative colitis. Of these patients, 41 were on infliximab and 12 on adalimumab. The TDM performed in front of a primary non-response in 18 patients, and a loss of secondary response in 34 patients. We found immunization in 28% of patients, underdosage in 56%, and 15% had a normal dosage. Therapeutic optimization was adopted in 52% of patients, a switch in 19%, a swap in 25% of patients, and the addition of an immunosuppressant in 6.5%. The evolution was marked by the achievement of a prolonged remission in 69% of these patients. Conclusion: Pharmacological dosage of the residual rate of the anti-TNF and anti-drug antibodies currently constitutes an important element for managing the primary non-response or the loss of secondary response to anti-TNF in patients with IBD treated by biotherapy.
Author Keywords: IBD, Crohn’s disease, Ulcerative colitis, Anti-TNF, Pharmacological dosage, Therapeutic Drug Monitoring.
Imane Radouane1, S. Ouahid2, Hasna Igorman3, Rachid Laroussi4, Abdelfettah Touibi5, Sanaa Berrag6, Tarik Adioui7, and Mouna Tamzaourte8
1 Department of Gastroenterology I, Military Hospital, Mohamed V University of Rabat, Morocco
2 Service de Gastroentérologie clinique, Hôpital Militaire d’Instructions Mohammed V, Rabat, Morocco
3 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
4 Department of Gastroenterology I, Military Hospital, Mohamed V University of Rabat, Morocco
5 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
6 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
7 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
8 Department of Gastroenterology, Military Hospital Mohammed V, Rabat, Morocco
Original language: English
Copyright © 2023 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: The advent of biotherapies has radically changed the management of IBD. However, the use of these drugs may in some cases result in to primary non-response or a loss of secondary response. Therapeutic Drug Monitoring (TDM) is a tool that was developed to manage biotherapy as accurately as possible in these situations. Material and methods: This is a retrospective descriptive study spread over 8 years of 53 patients followed for IBD put on anti-TNF(, in whom assays of residual levels of anti-TNF and anti-drug antibodies were carried out. Results: 48 suffer from Crohn’s disease and 5 from ulcerative colitis. Of these patients, 41 were on infliximab and 12 on adalimumab. The TDM performed in front of a primary non-response in 18 patients, and a loss of secondary response in 34 patients. We found immunization in 28% of patients, underdosage in 56%, and 15% had a normal dosage. Therapeutic optimization was adopted in 52% of patients, a switch in 19%, a swap in 25% of patients, and the addition of an immunosuppressant in 6.5%. The evolution was marked by the achievement of a prolonged remission in 69% of these patients. Conclusion: Pharmacological dosage of the residual rate of the anti-TNF and anti-drug antibodies currently constitutes an important element for managing the primary non-response or the loss of secondary response to anti-TNF in patients with IBD treated by biotherapy.
Author Keywords: IBD, Crohn’s disease, Ulcerative colitis, Anti-TNF, Pharmacological dosage, Therapeutic Drug Monitoring.
How to Cite this Article
Imane Radouane, S. Ouahid, Hasna Igorman, Rachid Laroussi, Abdelfettah Touibi, Sanaa Berrag, Tarik Adioui, and Mouna Tamzaourte, “The value of pharmacological dosage in the management of chronic inflammatory bowel disease treated with anti-TNF agents,” International Journal of Innovation and Applied Studies, vol. 40, no. 1, pp. 279–290, July 2023.
